Your Article Summary
See Latest ArticlesMerck Serono: European Commission Approves Erbitux for 1st-Line Use in Head and Neck Cancer
PharmiWeb, 12/02/08
Merck Serono, a division of Merck KGaA, announced that it has received approval from the European Commission to extend the use of its targeted therapy Erbitux (cetuximab) to include 1st-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN). Erbitux was previously approved for use in combination with radiotherapy for locally advanced disease.
Today in Drug/Product Approvals...keeping you current
Receive free subspecialty "5-minute updates" via email
Ustekinumab (Stelara): First-in-class human monoclonal antibody approved for treatment of moderate-to-severe plaque psoriasis
Formulary , 12/02/09
Safety concerns slow new drug review and approval processes
Formulary , 12/02/09
Teva Announces The Submission Of A Biologics License Application (BLA) For XM02 For The Treatment Of Chemotherapy-Induced Neutropenia
Teva Pharmaceutical Industries, 12/02/09